Takeda Pharmaceutical Company

Takeda_global_headquarters.jpg

Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō Kabushiki-gaisha) is a multinational pharmaceutical company headquartered in Tokyo, Japan. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.

History

Takeda was founded in 1781 by Chobei Takeda I, who began selling traditional Japanese and Chinese herbal medicines in Doshomachi, Osaka. The company was incorporated in 1925 and has since grown through various acquisitions and mergers, including the notable acquisition of Shire in 2019, which significantly expanded its global footprint and product portfolio.

Operations

Takeda operates in over 80 countries and regions, with a strong presence in the United States, Europe, and Asia. The company's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases. Takeda is also involved in the development of vaccines.

Products

Takeda's product portfolio includes a wide range of prescription medications and over-the-counter products. Some of its well-known products include:

• Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease
• Ninlaro (ixazomib) for the treatment of multiple myeloma
• Trintellix (vortioxetine) for the treatment of major depressive disorder
• Adcetris (brentuximab vedotin) for the treatment of Hodgkin lymphoma and other types of lymphoma

Research and Development

Takeda invests heavily in research and development (R&D), with R&D centers located in Japan, the United States, and Europe. The company collaborates with various academic institutions, research organizations, and other pharmaceutical companies to advance its pipeline of innovative therapies.

Corporate Social Responsibility

Takeda is committed to corporate social responsibility (CSR) and sustainability. The company focuses on improving access to healthcare, supporting communities, and reducing its environmental impact. Takeda is a signatory of the United Nations Global Compact and aligns its CSR activities with the Sustainable Development Goals (SDGs).

Leadership

The current CEO of Takeda is Christophe Weber, who has been leading the company since 2015. Under his leadership, Takeda has undergone significant transformation, including the acquisition of Shire and a renewed focus on innovation and patient-centricity.

See also

• List of pharmaceutical companies
• Pharmaceutical industry
• Biotechnology
• Healthcare in Japan

External links

This article is a stub related to pharmacology. You can help WikiMD by expanding it!